|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RPL36AL |
Gene summary for RPL36AL |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RPL36AL | Gene ID | 6166 |
| Gene name | ribosomal protein L36a like | |
| Gene Alias | RPL36A | |
| Cytomap | 14q21.3 | |
| Gene Type | protein-coding | GO ID | GO:0006412 | UniProtAcc | Q969Q0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6166 | RPL36AL | GSM4909281 | Human | Breast | IDC | 3.52e-06 | -2.74e-01 | 0.21 |
| 6166 | RPL36AL | GSM4909282 | Human | Breast | IDC | 7.76e-05 | -2.48e-01 | -0.0288 |
| 6166 | RPL36AL | GSM4909286 | Human | Breast | IDC | 8.11e-36 | -4.15e-01 | 0.1081 |
| 6166 | RPL36AL | GSM4909287 | Human | Breast | IDC | 3.55e-04 | -3.08e-01 | 0.2057 |
| 6166 | RPL36AL | GSM4909288 | Human | Breast | IDC | 5.89e-07 | -3.53e-01 | 0.0988 |
| 6166 | RPL36AL | GSM4909290 | Human | Breast | IDC | 2.65e-09 | 2.26e-01 | 0.2096 |
| 6166 | RPL36AL | GSM4909293 | Human | Breast | IDC | 2.40e-13 | -2.47e-01 | 0.1581 |
| 6166 | RPL36AL | GSM4909294 | Human | Breast | IDC | 1.44e-03 | -2.16e-01 | 0.2022 |
| 6166 | RPL36AL | GSM4909296 | Human | Breast | IDC | 9.53e-03 | -1.31e-01 | 0.1524 |
| 6166 | RPL36AL | GSM4909297 | Human | Breast | IDC | 3.07e-23 | -2.80e-01 | 0.1517 |
| 6166 | RPL36AL | GSM4909298 | Human | Breast | IDC | 4.65e-11 | -2.44e-01 | 0.1551 |
| 6166 | RPL36AL | GSM4909301 | Human | Breast | IDC | 5.72e-10 | -4.59e-01 | 0.1577 |
| 6166 | RPL36AL | GSM4909306 | Human | Breast | IDC | 3.98e-03 | -2.32e-01 | 0.1564 |
| 6166 | RPL36AL | GSM4909309 | Human | Breast | IDC | 1.56e-03 | -1.37e-01 | 0.0483 |
| 6166 | RPL36AL | GSM4909311 | Human | Breast | IDC | 1.04e-46 | -5.28e-01 | 0.1534 |
| 6166 | RPL36AL | GSM4909312 | Human | Breast | IDC | 6.12e-09 | -3.84e-01 | 0.1552 |
| 6166 | RPL36AL | GSM4909313 | Human | Breast | IDC | 9.73e-05 | -1.41e-01 | 0.0391 |
| 6166 | RPL36AL | GSM4909316 | Human | Breast | IDC | 4.32e-09 | -4.44e-02 | 0.21 |
| 6166 | RPL36AL | GSM4909318 | Human | Breast | IDC | 2.98e-02 | -7.17e-02 | 0.2031 |
| 6166 | RPL36AL | GSM4909319 | Human | Breast | IDC | 3.32e-75 | -8.41e-01 | 0.1563 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0301018 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
| hsa0517118 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
| hsa0301019 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
| hsa0517119 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
| hsa0301024 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
| hsa0517124 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
| hsa0301034 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
| hsa0517134 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
| hsa0301044 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
| hsa0517144 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
| hsa0301054 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
| hsa0517154 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
| hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa0301020 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
| hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa03010110 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
| hsa0301025 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
| hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
| hsa0301035 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
| hsa0517135 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
| Page: 1 2 3 4 5 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RPL36AL | SNV | Missense_Mutation | rs762762169 | c.163A>G | p.Ile55Val | p.I55V | Q969Q0 | protein_coding | tolerated(0.34) | benign(0.047) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RPL36AL | SNV | Missense_Mutation | novel | c.179N>T | p.Ala60Val | p.A60V | Q969Q0 | protein_coding | tolerated(0.06) | probably_damaging(0.936) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RPL36AL | SNV | Missense_Mutation | rs770211653 | c.170N>A | p.Arg57Gln | p.R57Q | Q969Q0 | protein_coding | tolerated(0.47) | benign(0.014) | TCGA-D1-A167-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RPL36AL | SNV | Missense_Mutation | novel | c.315G>T | p.Gln105His | p.Q105H | Q969Q0 | protein_coding | deleterious(0.02) | possibly_damaging(0.614) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RPL36AL | SNV | Missense_Mutation | novel | c.247N>A | p.Leu83Met | p.L83M | Q969Q0 | protein_coding | deleterious(0.03) | probably_damaging(0.971) | TCGA-EY-A5W2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RPL36AL | SNV | Missense_Mutation | novel | c.119N>A | p.Arg40His | p.R40H | Q969Q0 | protein_coding | tolerated(0.26) | benign(0.013) | TCGA-EY-A5W2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RPL36AL | SNV | Missense_Mutation | novel | c.157N>C | p.Lys53Gln | p.K53Q | Q969Q0 | protein_coding | deleterious(0.01) | possibly_damaging(0.589) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RPL36AL | SNV | Missense_Mutation | novel | c.179N>G | p.Ala60Gly | p.A60G | Q969Q0 | protein_coding | deleterious(0.02) | benign(0.35) | TCGA-91-6830-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| RPL36AL | SNV | Missense_Mutation | novel | c.47N>A | p.Gly16Asp | p.G16D | Q969Q0 | protein_coding | tolerated(0.05) | benign(0.018) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
| RPL36AL | SNV | Missense_Mutation | c.97N>G | p.Leu33Val | p.L33V | Q969Q0 | protein_coding | deleterious(0.04) | benign(0.026) | TCGA-BJ-A4O8-01 | Thyroid | thyroid carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |